<DOC>
	<DOCNO>NCT00701857</DOCNO>
	<brief_summary>RATIONALE : Pemetrexed may stop growth tumor cell block enzymes need cell growth . Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Cisplatin may make tumor cell sensitive radiation therapy . Giving pemetrexed together cisplatin radiation therapy may kill tumor cell . PURPOSE : This phase I trial study side effect best dose pemetrexed give together cisplatin radiation therapy treat patient stage III stage IV esophageal cancer gastroesophageal junction cancer .</brief_summary>
	<brief_title>Pemetrexed , Cisplatin , Radiation Therapy Treating Patients With Esophageal Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To establish maximum tolerate dose pemetrexed disodium combination cisplatin standard-dose radiotherapy patient stage III IV esophageal gastroesophageal junction carcinoma . Secondary - To specifically characterize toxicity profile regimen . - To investigate , preliminarily , anti-tumor activity regimen , measure standard response criterion ( RECIST criterion ) , patient measurable disease . OUTLINE : This dose-escalation study pemetrexed disodium . Patients receive pemetrexed disodium IV 10 minute day 1 , 15 , 29 cisplatin IV 10 minute day 1 , 8 , 15 , 22 , 29 . Patients also undergo external beam radiotherapy daily , 5 day week , 6 week . After completion study therapy , patient follow 30 day every 3 month 1 year .</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis esophageal gastroesophageal junction carcinoma Stage III IV disease Treatment chemoradiotherapy consider appropriate Measurable evaluable disease Clinically significant pleural pericardial effusion ascites allow provided drain prior study entry No pleurodesis within past 2 week Controlled brain metastasis allow provided patient clinically stable sign progression MRI CT scan brain ≥ 60 day completion treatment AND asymptomatic require steroid PATIENT CHARACTERISTICS : ECOG performance status 02 Life expectancy ≥ 12 week WBC ≥ 2,500/mm^3 ANC ≥ 1,500/mm^3 Hemoglobin ≥ 9 g/dL Platelet count ≥ 100,000/mm^3 Total bilirubin normal Alkaline phosphatase AND AST ALT meeting follow criterion : Alkaline phosphatase normal AND AST ALT ≤ 3 time upper limit normal ( ULN ) ( ≤ 5 time ULN patient liver metastasis ) Alkaline phosphatase ≤ 2.5 time ULN AND AST ALT ≤ 1.5 time ULN Alkaline phosphatase ≤ 5 time ULN AND AST ALT normal Creatinine clearance ≥ 45 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 3 month completion study therapy Able take folic acid , vitamin B_12 , corticosteroids No know severe hypersensitivity reaction study drug No uncontrolled serious active infection No preexist peripheral neuropathy &gt; grade 1 No significant cardiac disease , include follow : Uncontrolled high blood pressure Unstable angina Congestive heart failure within past 6 month Left ventricular ejection fraction lower limit normal Myocardial infarction within past year Serious cardiac arrhythmia require medication PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior systemic therapy regimens No prior radiotherapy gastric/esophageal field No aspirin NSAID pemetrexed disodium administration No concurrent colonystimulating factor ( CSF ) maintain WBC ANC eligibility value</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>stage III esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
</DOC>